Difference between revisions of "Team:SMMU-China/Questionaire-interview"

Line 107: Line 107:
 
<!-- <p style="text-align: center;">Lorem ipsum dolor sit amet feugiat</p> -->
 
<!-- <p style="text-align: center;">Lorem ipsum dolor sit amet feugiat</p> -->
 
</header>
 
</header>
−
 
+
<p class="inner-text">
 +
In order to promote synthetic biology and iGEM program, exploring the issues of rigor and biosafety and improving our project design, we were lucky to interview several experts in thoracic surgery and cardiology.
 +
</p>
 
<div class="data-scientists-picture">
 
<div class="data-scientists-picture">
 
<div class="person-container">
 
<div class="person-container">
Line 148: Line 150:
 
</div>
 
</div>
 
</div>
 
</div>
 +
<div class="person-container">
 +
<a href="#interview_charlie">
 +
                <div class="person-photo">
 +
                  <span></span>
 +
                </div>
 +
              </a>
 +
<div class="person-name">
 +
<p class="name-text">Charlie</p>
 +
</div>
 +
<div class="person-job">
 +
<p class="job-text">博士，教授</p>
 +
</div>
 +
</div>
 
</div>
 
</div>
 +
<div style="text-align:center" class="resultimage">
 +
<img src="https://static.igem.org/mediawiki/2018/f/f6/T--SMMU-China--test_image.jpg" style="width: 60%;">
 +
<p style="font-style: italic;text-align: center;padding: 0em 100px 1em;">
 +
<strong>Dr. Zhao Xianxian, Depart. Of Cardiology, Shanghai Changhai Hospital</strong>
 +
</p>
 +
</div>
 +
<p class="inner-text">
 +
Prof. Zhao is mainly engaged in the clinical treatment of cardiovascular disease and heart failure. He pointed out that the main clinical treatment for heart failure is medication currently. And the most important drug is the so-called Golden Triangle, which consist in ACEi/ARB, βRB, diuretic. After decades of clinical practice, medications have been matured. However, these drugs can only delay the symptoms and do not improve or psrolong the patient's survival time. Therefore, the prospect of gene therapy is broad.
 +
</p>
 +
<p class="inner-text">
 +
In addition, Professor Zhao gave a high evaluation to our project, and his speech was very inspiring for us.
 +
</p>
 +
<div style="text-align:center" class="resultimage">
 +
<img src="https://static.igem.org/mediawiki/2018/f/f6/T--SMMU-China--test_image.jpg" style="width: 60%;">
 +
<p style="font-style: italic;text-align: center;padding: 0em 100px 1em;">
 +
<strong> Dr. He Zhiqing, Depart. Of Cardiology, Shanghai Changzheng Hospital</strong>
 +
</p>
 +
</div>
 +
<p class="inner-text">
 +
Dr. He is mainly engaged in basic research on heart failure treatment. He pointed out that organisms have evolved a complete immune system for targeted clearance of exogenous proteins. Therefore, whether the plasmids and antibodies we introduce can escape the immune system is a key to success. In addition, if the idea of introducing exogenous genes into mammals or humans will cause genetic contamination remains to be discussed.
 +
</p>
 +
<p class="inner-text">
 +
In general, Dr. He’s opinion was very instructive for us, and we finally decided to use intracellular antibodies to avoid the humoral immune system.
 +
</p>
 +
<div style="text-align:center" class="resultimage">
 +
<img src="https://static.igem.org/mediawiki/2018/f/f6/T--SMMU-China--test_image.jpg" style="width: 60%;">
 +
<p style="font-style: italic;text-align: center;padding: 0em 100px 1em;">
 +
<strong> Dr. Wang Zhinong, Depart. Of Cardiothoracic Surgery, Shanghai Changzheng Hospital</strong>
 +
</p>
 +
</div>
 +
<p class="inner-text">
 +
Prof. Wang specializes in cardiovascular diseases and surgical treatment of atrial fibrillation. Heart failure is not only a disease, but also an economic burden for a patient. It also imposes a huge burden on the family and society. He pointed out that heart failure is not only a disease. It contains acute and chronic heart failure, but also causes a variety of other heart diseases. Our project is based on calcium disorders and may have a positive impact on myocardial micro-remodeling. But we can't just confine ourselves to this aspect, we must broaden our horizons. He hopes that we can communicate more with others, maintain the spirit of exploration, and keep moving forward.
 +
</p>
 +
<div style="text-align:center" class="resultimage">
 +
<img src="https://static.igem.org/mediawiki/2018/f/f6/T--SMMU-China--test_image.jpg" style="width: 60%;">
 +
<p style="font-style: italic;text-align: center;padding: 0em 100px 1em;">
 +
<strong> Dr. Liu Yang, Depart. Of Cardiothoracic Surgery, Shanghai Changhai Hospital</strong>
 +
</p>
 +
</div>
 +
<p class="inner-text">
 +
Dr. Liu mainly studies surgical treatment of coronary heart disease and aortic dissection. He said that the design principle of our project is very clever. However, gene transcription and translational expression take a long time, which limits its clinical application. For example, acute heart failure can only be treated by emergency medical intervention. At present, Entresto is a new-developed drug to treat heart failure. And its main components are Sacubitrilat and Valsartan, and its clinical effect is remarkable. However, it is worth mentioning that the prospect of gene therapy is broad, even if the research of stem cell therapy is progressing slowly.
 +
</p>
 +
<div style="text-align:center" class="resultimage">
 +
<img src="https://static.igem.org/mediawiki/2018/f/f6/T--SMMU-China--test_image.jpg" style="width: 60%;">
 +
<p style="font-style: italic;text-align: center;padding: 0em 100px 1em;">
 +
<strong> xxxxxx</strong>
 +
</p>
 +
</div>
 +
<p class="inner-text">
 +
We also listened a lecture on cell therapy given by professor Erwin Neher, a Nobel laureate. Prof. Erwin Neher specializes in cellular ion channel function. His work helped to explain the mechanism of heart disease. After the lecture, we presented our project to him. He speak highly on our project and encouraged us try to find out more courses for treatment on HF next year.
 +
</p>
 +
 +
 
<header>
 
<header>
 
<div id="interview_alpha" style="height: 30px"></div>
 
<div id="interview_alpha" style="height: 30px"></div>

Revision as of 11:36, 7 October 2018

interview alpha
interview beta
interview charlie

Question and interview

In order to promote synthetic biology and iGEM program, exploring the issues of rigor and biosafety and improving our project design, we were lucky to interview several experts in thoracic surgery and cardiology.

Alpha

博士，教授

Beta

博士，教授

Charlie

博士，教授

Charlie

博士，教授

Dr. Zhao Xianxian, Depart. Of Cardiology, Shanghai Changhai Hospital

Prof. Zhao is mainly engaged in the clinical treatment of cardiovascular disease and heart failure. He pointed out that the main clinical treatment for heart failure is medication currently. And the most important drug is the so-called Golden Triangle, which consist in ACEi/ARB, βRB, diuretic. After decades of clinical practice, medications have been matured. However, these drugs can only delay the symptoms and do not improve or psrolong the patient's survival time. Therefore, the prospect of gene therapy is broad.

In addition, Professor Zhao gave a high evaluation to our project, and his speech was very inspiring for us.

Dr. He Zhiqing, Depart. Of Cardiology, Shanghai Changzheng Hospital

Dr. He is mainly engaged in basic research on heart failure treatment. He pointed out that organisms have evolved a complete immune system for targeted clearance of exogenous proteins. Therefore, whether the plasmids and antibodies we introduce can escape the immune system is a key to success. In addition, if the idea of introducing exogenous genes into mammals or humans will cause genetic contamination remains to be discussed.

In general, Dr. He’s opinion was very instructive for us, and we finally decided to use intracellular antibodies to avoid the humoral immune system.

Dr. Wang Zhinong, Depart. Of Cardiothoracic Surgery, Shanghai Changzheng Hospital

Prof. Wang specializes in cardiovascular diseases and surgical treatment of atrial fibrillation. Heart failure is not only a disease, but also an economic burden for a patient. It also imposes a huge burden on the family and society. He pointed out that heart failure is not only a disease. It contains acute and chronic heart failure, but also causes a variety of other heart diseases. Our project is based on calcium disorders and may have a positive impact on myocardial micro-remodeling. But we can't just confine ourselves to this aspect, we must broaden our horizons. He hopes that we can communicate more with others, maintain the spirit of exploration, and keep moving forward.

Dr. Liu Yang, Depart. Of Cardiothoracic Surgery, Shanghai Changhai Hospital

Dr. Liu mainly studies surgical treatment of coronary heart disease and aortic dissection. He said that the design principle of our project is very clever. However, gene transcription and translational expression take a long time, which limits its clinical application. For example, acute heart failure can only be treated by emergency medical intervention. At present, Entresto is a new-developed drug to treat heart failure. And its main components are Sacubitrilat and Valsartan, and its clinical effect is remarkable. However, it is worth mentioning that the prospect of gene therapy is broad, even if the research of stem cell therapy is progressing slowly.

xxxxxx

We also listened a lecture on cell therapy given by professor Erwin Neher, a Nobel laureate. Prof. Erwin Neher specializes in cellular ion channel function. His work helped to explain the mechanism of heart disease. After the lecture, we presented our project to him. He speak highly on our project and encouraged us try to find out more courses for treatment on HF next year.

Interview - Alpha

Vestibulum scelerisque ultricies libero id hendrerit. Vivamus malesuada quam faucibus ante dignissim auctor hendrerit libero placerat. Nulla facilisi. Proin aliquam felis non arcu molestie at accumsan turpis commodo. Proin elementum, nibh non egestas sodales, augue quam aliquet est, id egestas diam justo adipiscing ante. Pellentesque tempus nulla non urna eleifend ut ultrices nisi faucibus. Vestibulum scelerisque ultricies libero id hendrerit. Vivamus malesuada quam faucibus ante dignissim auctor hendrerit libero placerat. Nulla facilisi. Proin aliquam felis non arcu molestie at accumsan turpis commodo. Proin elementum, nibh non egestas sodales, augue quam aliquet est, id egestas diam justo adipiscing ante.

Praesent a dolor leo. Duis in felis in tortor lobortis volutpat et pretium tellus. Vestibulum ac ante nisl, a elementum odio. Duis semper risus et lectus commodo fringilla. Maecenas sagittis convallis justo vel mattis. placerat, nunc diam iaculis massa, et aliquet nibh leo non nisl vitae porta lobortis, enim neque fringilla nunc, eget faucibus lacus sem quis nunc suspendisse nec lectus sit amet augue rutrum vulputate ut ut mi. Aenean elementum, mi sit amet porttitor lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem ipsum dolor.

Interview - Beta

Elementum odio duis semper risus et lectus commodo fringilla. Maecenas sagittis convallis justo vel mattis. placerat, nunc diam iaculis massa, et aliquet nibh leo non nisl vitae porta lobortis, enim neque fringilla nunc, eget faucibus lacus sem quis nunc suspendisse nec lectus sit amet augue rutrum vulputate ut ut mi. Aenean elementum, mi sit amet porttitor lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem ipsum dolor sit amet nullam consequat feugiat dolore tempus. Elementum odio duis semper risus et lectus commodo fringilla. Maecenas sagittis convallis justo vel mattis. placerat, nunc diam iaculis massa, et aliquet nibh leo non nisl vitae porta lobortis, enim neque fringilla nunc, eget faucibus lacus sem quis nunc suspendisse nec lectus sit amet augue rutrum vulputate ut ut mi. Aenean elementum, mi sit amet porttitor lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem ipsum dolor.

Nunc diam iaculis massa, et aliquet nibh leo non nisl vitae porta lobortis, enim neque fringilla nunc, eget faucibus lacus sem quis nunc suspendisse nec lectus sit amet augue rutrum vulputate ut ut mi. Aenean elementum, mi sit amet porttitor lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem ipsum dolor sit amet nullam consequat feugiat dolore tempus.

Interview - Charlie

Nunc diam iaculis massa, et aliquet nibh leo non nisl vitae porta lobortis, enim neque fringilla nunc, eget faucibus lacus sem quis nunc suspendisse nec lectus sit amet augue rutrum vulputate ut ut mi. Aenean elementum, mi sit amet porttitor lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem ipsum dolor sit amet nullam consequat feugiat dolore tempus. Elementum odio duis semper risus et lectus commodo fringilla. Maecenas sagittis convallis justo vel mattis.

to the top